(Q35642536)

9 August 2017

1 reference

title

Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia (English)

1 reference

9 August 2017

Marc Esser

1

1 reference

9 August 2017

Helmut Brunner

series ordinal

2

1 reference

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

21

1 reference

9 August 2017

issue

18

1 reference

9 August 2017

page(s)

1295-1313

1 reference

Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

G-CSF as prophylaxis of febrile neutropenia in SCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Hematopoietic growth factors in the older cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262329

Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation

21 January 2018

1 reference

12 December 2020

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

1 reference

12 December 2020

Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials

1 reference

12 December 2020

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

1 reference

12 December 2020

An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children

1 reference

12 December 2020

Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model

1 reference

12 December 2020

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care

1 reference

12 December 2020

Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients

1 reference

12 December 2020

Colony-stimulating factors for the management of neutropenia in cancer patients

1 reference

12 December 2020

Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy

1 reference

12 December 2020

Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness

1 reference

12 December 2020

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

1 reference

12 December 2020

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials

1 reference

12 December 2020

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit

1 reference

12 December 2020

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

12 December 2020

Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay?

1 reference

12 December 2020

The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cells as rescue therapy following autologous bone marrow transplant

1 reference

12 December 2020

Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation

1 reference

12 December 2020

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

1 reference

12 December 2020

Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor

1 reference

12 December 2020

Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology

1 reference

12 December 2020

Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation

1 reference

12 December 2020

[Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology]

1 reference

12 December 2020

Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer.

1 reference

12 December 2020

Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation

1 reference

12 December 2020

Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03262329

1 reference

9 August 2017

1 reference